Potential clinical application of LCZ696 in patients with chronic heart failure in real life clinical practice: results from TREAT HF Study

被引：0
|
作者：
Cavusoglu, Y. [1 ]
Eraslan, S. [1 ]
Kaya, H. [2 ]
机构：
[1] Eskisehir Osmangazi Univ, Eskisehir, Turkey
[2] Cumhuriyet Univ, Cardiol, Sivas, Turkey
来源：
EUROPEAN HEART JOURNAL | 2016年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1124
引用
收藏
页码：204 / 204
页数：1
相关论文
共 50 条
  • [1] Potential use of LCZ696 in real life clinical practice in patients with chronic heart failure: Results from REALITY HF Study
    Cavusoglu, Y.
    Kozan, O.
    Temizhan, A.
    Kucukoglu, S.
    EUROPEAN HEART JOURNAL, 2016, 37 : 918 - 919
  • [2] POTENTIAL CLINICAL APPLICATION OF LCZ696 IN REAL LIFE CLINICAL PRACTICE BASED ON 2016 ACC/AHA/HFSA AND ESC HEART FAILURE GUIDELINES CRITERIA: RESULTS FROM TREAT HF STUDY
    Cavusoglu, Yuksel
    Kaya, Hakki
    Yilmaz, Mehmet Birhan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 920 - 920
  • [3] Potential clinical application of dapagliflozin in patients with chronic heart failure in real life clinical practice: Results from TREAT HF Study
    Cavusoglu, Y. Yuksel
    Kaya, H.
    Yilmaz, M. B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 275 - 276
  • [4] Potantial clinical application of potassium binders in patients with chronic heart failure in real life clinical practice: results from TREAT HF study
    Cavusoglu, Y.
    Kaya, H.
    Murat, S.
    Yilmaz, B.
    EUROPEAN HEART JOURNAL, 2020, 41 : 1052 - 1052
  • [5] Prevalence of hyperkalemia in patients with chronic heart failure in real life clinical practice: Results from TREAT HF Study
    Cavusoglu, Y.
    Kaya, H.
    Murat, S.
    Yilmaz, M. B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 336 - 336
  • [6] Hyperkalemia in heart failure patients with renal dysfunction in real life clinical practice: Results from TREAT HF Study
    Cavusoglu, Y.
    Kaya, H.
    Murat, S.
    Yilmaz, M. B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 184 - 184
  • [7] How many patients with chronic heart failure will be eligible for LCZ696 in the community?
    Pellicori, P. Pierpaolo
    Urbinati, A.
    Shah, P.
    Macnamara, A.
    Kazmi, S.
    Dierckx, R.
    Cleland, J. G. F.
    Clark, A. L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 235 - 235
  • [8] A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
    McMurray, John
    Packer, Milton
    Desai, Akshay
    Gong, Jianjian
    Greenlaw, Nicola
    Lefkowitz, Martin
    Rizkala, Adel
    Shi, Victor
    Rouleau, Jean
    Solomon, Scott
    Swedberg, Karl
    Zile, Michael R.
    Andersen, Karl
    Arango, Juan Luis
    Arnold, Malcolm
    Belohlavek, Jan
    Boehm, Michael
    Boytsov, Sergey
    Burgess, Lesley
    Cabrera, Walter
    Chen, Chen-Huan
    Erglis, Andrejs
    Fu, Michael
    Gomez, Efrain
    Gonzalez, Angel
    Hagege, Albert-Alain
    Katova, Tzvetana
    Kiatchoosakun, Songsak
    Kim, Kee-Sik
    Bayram, Edmundo
    Martinez, Felipe
    Merkely, Bela
    Mendoza, Ivan
    Mosterd, Arend
    Negrusz-Kawecka, Marta
    Peuhkurinen, Keijo
    Ramires, Felix
    Refsgaard, Jens
    Senni, Michele
    Sibulo, Antonio S., Jr.
    Silva-Cardoso, Jose
    Squire, Iain
    Starling, Randall C.
    Vinereanu, Dragos
    Teerlink, John R.
    Wong, Raymond
    EUROPEAN HEART JOURNAL, 2015, 36 (07) : 434 - 439
  • [9] Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice
    Filippatos, Gerasimos
    Farmakis, Dimitrios
    Parissis, John
    Lekakis, John
    BMC MEDICINE, 2015, 13
  • [10] Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice
    Gerasimos Filippatos
    Dimitrios Farmakis
    John Parissis
    John Lekakis
    BMC Medicine, 13
12345